Effect of treatment with simvastatin on serum cholestryl ester transfer in patients on dialysis | Zendy

Robert Walker | Zendy; W. H. F. Sutherland | Zendy; Heather Walker | Zendy; Stephen MacMahon | Zendy; Richard A. Robson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of treatment with simvastatin on serum cholestryl ester transfer in patients on dialysis

Author(s) -

Robert Walker,

W. H. F. Sutherland,

Heather Walker,

Stephen MacMahon,

Richard A. Robson

Publication year - 1997

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/12.1.87

Subject(s) - simvastatin , apolipoprotein b , medicine , endocrinology , sterol o acyltransferase , dialysis , cholesterylester transfer protein , cholesteryl ester , cholesterol , lipoprotein , reductase , chemistry , biochemistry , enzyme

Plasma cholesteryl ester transfer activity is increased in patients with chronic renal failure on dialysis who have elevated levels of apolipoprotein B (apoB)-containing lipoproteins. Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, reduces levels of these lipoproteins but the effect of treatment on cholesteryl ester transfer activity in patients on dialysis remains to be determined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research